Deborah R Taylor

Summary

Affiliation: Food and Drug Administration
Country: USA

Publications

  1. doi request reprint Evolution of cell culture systems for HCV
    Deborah R Taylor
    Center for Biologics and Evaluation, Food and Drug Administration, Bethesda, MD, USA
    Antivir Ther 18:523-30. 2013
  2. ncbi request reprint Innate immunity and hepatitis C virus: eluding the host cell defense
    Deborah R Taylor
    Laboratory of Hepatitis and Related Emerging Agents, Division of Emerging and Transfusion Transmitted Diseases, Office of Blood Research and Review, CBER FDA, Bethesda, MD 20892, USA
    Front Biosci (Landmark Ed) 14:4950-61. 2009
  3. pmc Persistent growth of a human plasma-derived hepatitis C virus genotype 1b isolate in cell culture
    Erica Silberstein
    Division of Emerging and Transfusion Transmitted Diseases, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland, USA
    PLoS Pathog 6:e1000910. 2010
  4. pmc Altering SARS coronavirus frameshift efficiency affects genomic and subgenomic RNA production
    Ewan P Plant
    Laboratory of Emerging Pathogens, Division of Transfusion Transmitted Diseases, Food and Drug Administration, Bethesda, Maryland 20892, USA
    Viruses 5:279-94. 2013
  5. pmc Achieving a golden mean: mechanisms by which coronaviruses ensure synthesis of the correct stoichiometric ratios of viral proteins
    Ewan P Plant
    Laboratory of Hepatitis and Related Emerging Agents, Division of Emerging and Transfusion Transmitted Diseases, Office of Blood Research and Review, CBER, FDA, 8800 Rockville Pike, HFM310, Bethesda, Maryland 20892, USA
    J Virol 84:4330-40. 2010
  6. ncbi request reprint Severe acute respiratory syndrome coronavirus infection in vaccinated ferrets
    Miriam E R Darnell
    Laboratory of Hepatitis and Related Emerging Agents, Division of Emerging and Transfusion Transmitted Diseases, Office of Blood Research and Review, CBER FDA, Bethesda, MD 20892, USA
    J Infect Dis 196:1329-38. 2007
  7. pmc New antiviral pathway that mediates hepatitis C virus replicon interferon sensitivity through ADAR1
    Deborah R Taylor
    CBER FDA, HFM 448, 8800 Rockville Pike, Bethesda, MD 20892, USA
    J Virol 79:6291-8. 2005
  8. ncbi request reprint Evaluation of inactivation methods for severe acute respiratory syndrome coronavirus in noncellular blood products
    Miriam E R Darnell
    Center for Biologics Evaluation and Research, U S Food and Drug Administration, Bethesda, Maryland, USA
    Transfusion 46:1770-7. 2006

Collaborators

Detail Information

Publications8

  1. doi request reprint Evolution of cell culture systems for HCV
    Deborah R Taylor
    Center for Biologics and Evaluation, Food and Drug Administration, Bethesda, MD, USA
    Antivir Ther 18:523-30. 2013
    ..Many cell culture systems have used genetically-engineered viruses to gain growth in culture through the use of replicons, but recent advances using natural isolates may improve the outlook for progress in HCV research. ..
  2. ncbi request reprint Innate immunity and hepatitis C virus: eluding the host cell defense
    Deborah R Taylor
    Laboratory of Hepatitis and Related Emerging Agents, Division of Emerging and Transfusion Transmitted Diseases, Office of Blood Research and Review, CBER FDA, Bethesda, MD 20892, USA
    Front Biosci (Landmark Ed) 14:4950-61. 2009
    ..Here we review the different ways that HCV evades the immune response elicited by IFN...
  3. pmc Persistent growth of a human plasma-derived hepatitis C virus genotype 1b isolate in cell culture
    Erica Silberstein
    Division of Emerging and Transfusion Transmitted Diseases, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland, USA
    PLoS Pathog 6:e1000910. 2010
    ..This virus constitutes a novel tool for the study of one of the most relevant strains of HCV, genotype 1b, which will now be available for HCV life cycle research and useful for the development of new therapeutics...
  4. pmc Altering SARS coronavirus frameshift efficiency affects genomic and subgenomic RNA production
    Ewan P Plant
    Laboratory of Emerging Pathogens, Division of Transfusion Transmitted Diseases, Food and Drug Administration, Bethesda, Maryland 20892, USA
    Viruses 5:279-94. 2013
    ..The data suggest that either the RNA sequence or the ratio of viral proteins resulting from different levels of frameshifting affects viral replication...
  5. pmc Achieving a golden mean: mechanisms by which coronaviruses ensure synthesis of the correct stoichiometric ratios of viral proteins
    Ewan P Plant
    Laboratory of Hepatitis and Related Emerging Agents, Division of Emerging and Transfusion Transmitted Diseases, Office of Blood Research and Review, CBER, FDA, 8800 Rockville Pike, HFM310, Bethesda, Maryland 20892, USA
    J Virol 84:4330-40. 2010
    ..The findings of these analyses all support a "golden mean" model in which viruses use both programmed ribosomal frameshifting and translational attenuation to control the relative ratios of their encoded proteins...
  6. ncbi request reprint Severe acute respiratory syndrome coronavirus infection in vaccinated ferrets
    Miriam E R Darnell
    Laboratory of Hepatitis and Related Emerging Agents, Division of Emerging and Transfusion Transmitted Diseases, Office of Blood Research and Review, CBER FDA, Bethesda, MD 20892, USA
    J Infect Dis 196:1329-38. 2007
    ..Previous vaccine reports have noted robust neutralizing antibody and inflammatory responses in ferrets, resulting in enhanced hepatitis...
  7. pmc New antiviral pathway that mediates hepatitis C virus replicon interferon sensitivity through ADAR1
    Deborah R Taylor
    CBER FDA, HFM 448, 8800 Rockville Pike, Bethesda, MD 20892, USA
    J Virol 79:6291-8. 2005
    ..These results may explain successful HCV replicon clearance by IFN-alpha in vitro and may provide a promising new therapeutic strategy for HCV as well as other viral infections...
  8. ncbi request reprint Evaluation of inactivation methods for severe acute respiratory syndrome coronavirus in noncellular blood products
    Miriam E R Darnell
    Center for Biologics Evaluation and Research, U S Food and Drug Administration, Bethesda, Maryland, USA
    Transfusion 46:1770-7. 2006
    ..Effective methods for inactivating the SARS-CoV in protein solutions are described in this report...